Pfizer COVID-19 vaccine final data released: 95% effective
Pfizer COVID-19 vaccine final data released: 95% effective. On November 18th, Pfizer announced the final data of its Phase III clinical trial of the COVID-19 vaccine, with an effective rate of 95% and an effective rate of 94% for people over 65.
A total of 43,000 volunteers were enrolled in the trial. Currently, 8 subjects in the vaccine group and 162 subjects in the placebo group were infected, reaching the expected end point of the trial. One person in the vaccine group and 9 persons in the placebo group developed severe infections.
Through the follow-up of 8,000 subjects over 18 years of age after vaccination, no serious safety risks have been found for the vaccine. Grade 3 serious adverse events with a probability of ≥ 2% are fatigue (3.8%) and headache (2.0%).
In terms of vaccine distribution, Pfizer stated that it will use a specially developed transportation device with a temperature controlled at -70°C±10°C for vaccine transportation. The vaccine can be stored in this container for 15 days.
Pfizer plans to submit an emergency use authorization to the US FDA within a few days and share data with other regulatory agencies around the world.
According to current forecasts, Pfizer expects to produce as many as 50 million doses of vaccines worldwide by 2020 and 1.3 billion doses by the end of 2021.